Discovery awaits you at the 81st Scientific Sessions

Advance Program

scientificsessions.diabetes.org

#ADA2021
ABOUT THE MEETING
The Scientific Sessions offers researchers and health care professionals the unique opportunity to share ideas and learn about the significant advances and breakthroughs in diabetes.

Participants will receive exclusive access to more than 180 sessions and 1,000 original research presentations, take part in provocative and engaging exchanges with leading diabetes experts, expand their professional networks, and so much more.

The program is categorized into eight distinct theme areas, allowing participants to focus on their specialty or expand their knowledge in other areas.

Theme Areas:
- Acute and Chronic Complications
- Behavioral Medicine, Clinical Nutrition, Education, and Exercise
- Clinical Diabetes/Therapeutics
- Epidemiology/Genetics
- Immunology/Transplantation
- Insulin Action/Molecular Metabolism
- Integrated Physiology/Obesity
- Islet Biology/Insulin Secretion

Don’t miss this opportunity to join your colleagues at the world’s largest, most prestigious meeting on diabetes — The American Diabetes Association’s 81st Scientific Sessions (#ADA2021)!

FORMAT AND DATES
While we were hoping to meet in person this June, the health and safety of our attendees, staff, and exhibitors remains the top priority of the American Diabetes Association® (ADA) — which is why we have made the decision to transition the 2021 Scientific Sessions to a virtual meeting.

You can rest assured that the virtual 81st Scientific Sessions will continue to offer the latest groundbreaking science that you have come to expect from the ADA.

All pre-recorded sessions will be released during the original scheduled times over the five-day meeting, beginning on Friday, June 25 at 11:30 a.m., and concluding on Tuesday, June 29 at 12:15 p.m. ET (United States Eastern Time). All registered attendees will receive unlimited access to all virtual content for 90-days after the meeting.

LEARNING OBJECTIVES
The Scientific Sessions offers comprehensive educational programming covering the latest in the field of diabetes. The program is designed for physicians, scientists, researchers, nurses, dietitians, pharmacists, psychologists, and other health care professionals.

At the conclusion of this activity attendees will be able to:
- Identify the 2021 ADA Standards of Care for classifying, diagnosing, preventing, and treating prediabetes and diabetes
- Assess non-pharmacologic treatment options for individualizing treatment protocols for the management of hyperglycemia and hypoglycemia
- Apply clinical decision-making tools to the assessment and treatment of the complications related to diabetes
- Develop a more aggressive, effective, physiological, psychological, and behavioral treatment plan for patients with diabetes
- Cite the research into current, emerging, and novel therapies for type 1 and type 2 diabetes
- Discuss proven education strategies for increasing the impact of diabetes education with individual patients
- Interpret the latest findings in the areas of epidemiology, genetics, immunology, transplantation, and islet biology as they relate to diabetes

2021 NATIONAL SCIENTIFIC & HEALTH CARE ACHIEVEMENT AWARD RECIPIENTS

Banting Medal for Scientific Achievement
Jens J. Holst, MD, DMSc

Outstanding Scientific Achievement Award
Kristen J. Nadeau, MD, MSPH

Albert Renold Award
Bruce M. Spiegelman, PhD

Outstanding Achievement in Clinical Diabetes Award
Hans-Henrik D. Parving, MD

Outstanding Educator in Diabetes Award
Denise Charron-Prochownik, PhD, CPNP

Outstanding Physician Clinician in Diabetes Award
Silvio E. Inzucchi, MD

Harold Rifkin Award for Distinguished International Service in the Cause of Diabetes
Juleen R. Zierath, PhD

Kelly West Award for Outstanding Achievement in Epidemiology
Nicholas Wareham, MD, MPH

2021 INTEREST GROUP LECTURE AWARDS

Roger Pecoraro Award (Interest Group on Foot Care)
Edward J. Boyko, MD, MPH

Edwin Bierman Award (Interest Group on Complications)
Russell Debose-Boyd, PhD

Norbert Freinkel Award (Interest Group on Pregnancy)
Denice Feig, MD, MSc, FRCPC

Richard R. Rubin Award (Interest Group on Behavioral Medicine & Psychology)
David G. Marrero, PhD

Lois Jovanovic Transformative Woman in Diabetes Award (Women’s Interprofessional Network of the American Diabetes Association)
Linda M. Siminerio, RN, PhD, CDE

2021 NATIONAL SCIENTIFIC & HEALTH CARE ACHIEVEMENT AWARD RECIPIENTS

Banting Medal for Scientific Achievement
Jens J. Holst, MD, DMSc

Outstanding Scientific Achievement Award
Kristen J. Nadeau, MD, MSPH

Albert Renold Award
Bruce M. Spiegelman, PhD

Outstanding Achievement in Clinical Diabetes Award
Hans-Henrik D. Parving, MD

Outstanding Educator in Diabetes Award
Denise Charron-Prochownik, PhD, CPNP

Outstanding Physician Clinician in Diabetes Award
Silvio E. Inzucchi, MD

Harold Rifkin Award for Distinguished International Service in the Cause of Diabetes
Juleen R. Zierath, PhD

Kelly West Award for Outstanding Achievement in Epidemiology
Nicholas Wareham, MD, MPH
MEETING HIGHLIGHTS

Highly Anticipated Study Announcements
In addition to the over 180 sessions and 1,000 original research presentations, we are excited to announce that new data or updates to the following studies will be presented during the meeting:

- Efficacy and Safety of Dapagliflozin in Patients with and without Type 2 Diabetes Hospitalized with COVID-19 — Results from the DARE-19 Global Randomized Controlled Trial
- Results of the Glycemic Reduction Approaches in Diabetes — A Comparative Effectiveness (GRADE) Study
- Tirzepatide — A Novel Dual GIP/GLP-1RA — Results from the First Phase 3 SURPASS Clinical Trials
- Update on SCORED and SOLOIST Cardiovascular and Kidney Outcomes Trials

Mini-Symposia
Mini-Symposia are 1-hour sessions that normally include 1-2 speakers. Speakers present on a topic for a maximum of 20 minutes with the remainder of the time devoted to questions and discussion with the audience.

Professional Interest Groups
Professional Interest Group Discussions are held Saturday, Sunday, and Monday. Expect lively conversations, dialogue, and debate with professionals in your specialty such as islet biology, quality improvement, and technology. Learn more and join two groups today at professional.diabetes.org/interestgroups.

Oral Presentations
Abstracts selected for oral presentation are considered to be the best of the thousands of abstracts submitted to the Scientific Sessions. Choose from over 330 original presentations highlighting the most innovative research not found at any other meeting.

Virtual Poster Hall
View more than 1,000 ePosters and listen to recorded audio (if provided by the presenter) in the virtual poster hall. ePosters will be available for viewing throughout the entire meeting.

Abstract Availability
Abstract titles are scheduled to be available via the Scientific Sessions App on Friday, May 28. Embargoed text of abstracts will be made available on Tuesday, June 22.

Note: The abstract embargo still applies; however, abstracts are made available to attendees to assist in creating their itineraries for the meeting.

Earn Continuing Education Credits
Continuing Education Credit is available for physicians, family physicians, international physicians, physician assistants, nurses, pharmacists, dietitians, psychologists, social workers, and certified diabetes care and education specialists.

You’ll have the opportunity to earn 34.25 CE credits during the Live Virtual Meeting (June 25-29) AND up to 340 CE credits are available during the Post-Meeting Archive (June 30-September 29).

IMPORTANT DATES TO REMEMBER

- Last day to register at the Advance rate: May 13
- Last day to cancel meeting registration and receive a partial refund (50% of registration fee): May 13
Women's Inter-professional Network
The Women's Interprofessional Network of the American Diabetes Association (#WINADA) is our members-only network for female clinicians, scientists, educators, and other professionals in diabetes. WIN ADA will host multiple events at the Scientific Sessions, including an interactive discussion on the long-term professional impact of COVID-19 and a networking reception.

Learn more and become a WIN ADA member today at professional.diabetes.org/winada.

5K@ADA
Join us for the 5K@ADA Virtual Challenge anytime during June 25–27. Join people from across the globe and register today at ada5k.com.

SHOP DIABETES STORE
Visit the Shop Diabetes Store at shopdiabetes.org and save 30% on all books and official American Diabetes Association merchandise. Every purchase supports diabetes research, advocacy, and education programs.

ADA MEETING NEWS
Don’t miss the groundbreaking science from the Virtual 81st Scientific Sessions by visiting the meeting’s official online news source, ADAMeetingNews.org. Read live coverage of virtual presentations, get the latest news on upcoming sessions, follow what’s being talked about on social media, read presenter perspectives on their own presentations, and check back after the meeting for continued coverage through September. The site will be updated hourly during the Scientific Sessions and will include a full calendar of Industry-Supported Symposia and Innovation Theaters. Access ADAMeetingNews.org through your web browser or the Scientific Sessions Mobile App (available on iOS and Android).

PHOTOGRAPHY/SOCIAL MEDIA
Photography
Allowing photographs of presentation slides at the Scientific Sessions will be at the discretion of the presenter/study author. Each presenter/study author will announce, verbally and visually on a slide at the beginning of their presentation, whether or not they approve of photos/screen captures being taken of their slides. If allowed, attendees may take photos/screen captures during presentations provided that they are for personal, noncommercial use and are not for publication or rebroadcast without the express written permission of the author.

Social Media
The ADA encourages the use of social media, when following the above photo policy and within embargo restrictions, to update followers on the latest news coming from the Scientific Sessions. To engage on social media be sure to use the official meeting hashtag, #ADA2021, in all of your posts. You can also follow these channels for meeting updates:

- Twitter: @ADA_DiabetesPro and @AmDiabetesAssn
- Facebook: @DiabetesPro and @AmericanDiabetesAssociation
- Instagram: @AmDiabetesAssn
- LinkedIn: American-Diabetes-Association
REGISTER EARLY

The first 4,000 domestic attendees to register for the meeting will receive a Welcome Box delivered to their designated mailing address prior to the start of the meeting. Each box will include promotional items to add exciting physical elements to the virtual program.

Refer Your Colleagues. Reward Yourself
Share your interest in the science and reward yourself with prizes! From now until June 24, registered attendees who refer the highest number of new colleagues, or those who haven’t attended the Scientific Sessions within the past two years, will have the opportunity to win round trip coach air travel, four nights hotel, and complimentary meeting registration to attend the 82nd Scientific Sessions, June 3-7, 2022, in New Orleans, LA. In addition, the top five runner ups with the most referred colleagues will be awarded complimentary meeting registration to the 82nd Scientific Sessions in 2022.

To qualify, the referred colleague must enter your name in the referral question when registering for the meeting. Prizes awarded must be redeemed for the 82nd Scientific Sessions and are not transferrable. Hotel accommodations provided are at the discretion of the ADA.

See full promotion terms and conditions.

REGISTRATION RATES

<table>
<thead>
<tr>
<th>CATEGORY</th>
<th>ADVANCE 3/12/21 - 5/13/21</th>
<th>FINAL 5/14/21 - 9/29/21</th>
</tr>
</thead>
<tbody>
<tr>
<td>Member*</td>
<td>$449</td>
<td>$499</td>
</tr>
<tr>
<td>Non-Member</td>
<td>$649</td>
<td>$699</td>
</tr>
<tr>
<td>Student/Resident/Fellow</td>
<td>$159</td>
<td>$189</td>
</tr>
</tbody>
</table>

*To qualify for the Member rate your Medicine and Science or Health Care and Education Membership must be active through June 30, 2021 at the time of registration.

REGISTRATION CATEGORIES

Member
Medicine and Science or Health Care and Education Professional Members.

Have your Professional Member ID number available to register for the meeting as a member.

Non-Member
For those who are not Medicine and Science or Health Care and Education Professional Members.

Become a member when you register for the Scientific Sessions and save up to $200 on your registration.

Student/Resident/Fellow
Available to those currently enrolled in one of these programs. Proof of status in a program must be submitted in order to register.

Media Registration
The ADA provides complimentary access to the Scientific Sessions to credentialed members of the media, including print, broadcast, and online media for the express purpose of gathering news and information to produce press coverage of the 81st Scientific Sessions.

Media representatives welcome to attend include reporters, writers, photographers, and videographers. News organizations seeking media credentials must be represented by editorial staff.

For further information regarding registration eligibility and submission requirements for your news organization, contact SciSessionsPress@diabetes.org with any questions.

Warning/Be Aware!
There are companies that are claiming to offer registration services for ADA’s Scientific Sessions, which are not affiliated with ADA and do not offer any services on our behalf. You may receive emails or phone calls from these companies urging you to register. Registration should only be accessed from scientificsessions.diabetes.org, and reserved through ADA’s official registration provider, Convention Management Resources, (CMR). If you do not see this logo on the website, then they are not our official provider!
ACCREDITATION STATEMENTS AND CONTINUING EDUCATION CREDIT

For questions regarding continuing education, please contact professionaleducation@diabetes.org.

Physicians, Nurses, and Pharmacists

In support of improving patient care, the American Diabetes Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 34.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

Nurses: Pharmacotherapeutic change to CE credits offered up to 23.

Pharmacists: The Universal Activity Number is: JA4008193-0000-21-009-L01-P.

Note for Pharmacists: Upon closing of the online evaluation, the ADA will upload the pharmacy-related continuing education information to CPE Monitor within 60 days. Per ACPE rules, the ADA does not have access nor the ability to upload points requested after the evaluation closes.

Physicians for ABIM Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 34.25 Medical Knowledge only MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Note: Upon submission of the online evaluation, the MOC points will be immediately transferred to the ABIM. As previously stated and per the ABIM rules, the ADA does not have access nor the ability to upload points requested after the evaluation closes.

Physicians from Europe

UEMS/ACCME CME credit recognition: The American Medical Association (AMA) has an agreement of mutual recognition of CME credit with the UEMS. Under the terms of this agreement, the European Accreditation Council for Continuing Medical Education (EACCME), the accrediting arm of the UEMS, will convert CME credit for live activities certified by the AMA.

Family Physicians

Application for CME credit has been filed with the American Academy of Family Physicians. Determination of credit is pending.

Physician Assistants

The American Diabetes Association has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 34.25 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Dietitians

The American Diabetes Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 34.25 continuing professional education units (CPEUs) for completion of this program/material. Activity Number: 161537.

Psychologists

Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs.

Social Workers

As a Jointly Accredited Organization, the American Diabetes Association is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. The American Diabetes Association maintains responsibility for this course. Social workers completing this course receive 34.25 continuing education credits.

Certified Diabetes Educators

To satisfy the requirement for renewal of certification by continuing education for the National Certification Board for Diabetes Educators (NCBDE), continuing education activities must be diabetes related and approved by a provider on the NCBDE List of Approved Providers (www.ncbde.org). NCBDE does not approve continuing education. The American Diabetes Association is on the NCBDE List of Approved Providers.

To Obtain Continuing Education Credit

Certificates of Completion/Attendance are provided to registered attendees based upon completion of the online evaluation. The link to the online evaluation will be emailed to participants on June 25, 2021. The continuing education evaluation system will be available through October 4, 2021.
**DAY-AT-A-GLANCE SCHEDULE**

**FRIDAY, JUNE 25, 2021**

<table>
<thead>
<tr>
<th>Time</th>
<th>Acute and Chronic Complications</th>
<th>Behavioral Medicine, Clinical Nutrition, Education, and Exercise</th>
<th>Clinical Diabetes/Therapeutics</th>
<th>Epidemiology/Genetics</th>
<th>Immunology/Transplantation</th>
<th>Insulin Action/Molecular Metabolism</th>
<th>Integrated Physiology/Obesity</th>
<th>Islet Biology/Insulin Secretion</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30 a.m.-12:30 p.m.</td>
<td>Mini-Symposium The Impact of COVID-19 on Foot Care in Diabetes</td>
<td>Mini-Symposium Executive Function in Youth with Type 1 Diabetes — Driven to Diabetes Distraction</td>
<td>Mini-Symposium Diabetes Prevention in Vulnerable Populations</td>
<td>Mini-Symposium Resources for Interpreting Genetic Variants Associated with Diabetes and Obesity</td>
<td>Mini-Symposium Dietary Modulation of Nutrient Metabolism in Cancer</td>
<td>Mini-Symposium The Bile Acid Receptor FXR and the Microbiome</td>
<td>Mini-Symposium Debate — What’s the Hubbub about Beta-Cell Hubs?</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mini-Symposium Could Point-of-Care Devices Prove Useful in the Diagnosis of Diabetic Neuropathy in Clinical Practice?</td>
<td>Mini-Symposium Carbohydrate Intake and its Impact on Athletics and Health — A Debate</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| 12:45 p.m.-1:45 p.m. | Mini-Symposium We All Know What Causes Hypoglycemia, Don’t We? | Mini-Symposium Diabetes “Diets” since the Discovery of Insulin — Looking Back, Then to the Future | Mini-Symposium Are We There Yet? Initiating SGLT2 Inhibitors and/or GLP-1RAs in the Inpatient Cardiovascular Setting | Mini-Symposium Diabetes and the Brain across the Lifespan — Neurocognitive Deficits and Decline | Mini-Symposium Debate — Should Immune Intervention Trials Occur during the COVID-19 Pandemic? | Mini-Symposium Debate — Intergenerational Transmission of Obesity — Focus on the Womb or the Home? | Mini-Symposium Influence of Social Inequalities and Social Stress on Metabolic Health |
| | Mini-Symposium COVID-19 and Lipids — What’s the Connection? | Mini-Symposium COVID-19 and Beyond — Viruses in Pediatric Diabetes | | | | |
| | Mini-Symposium Identifying Patients at Risk — Kidney Disease Surveillance in Diabetes | | | | | |
| | Mini-Symposium Diabetes Retinopathy Detection and Treatment in Resource-Constrained Areas | | | |

Virtual Exhibits and Poster Hall: Available beginning at 11:30 a.m.
## DAY-AT-A-GLANCE SCHEDULE

### FRIDAY, JUNE 25, 2021 (CONTINUED)

<table>
<thead>
<tr>
<th>Time</th>
<th>Acute and Chronic Complications</th>
<th>Behavioral Medicine, Clinical Nutrition, Education, and Exercise</th>
<th>Clinical Diabetes/Therapeutics</th>
<th>Epidemiology/Genetics</th>
<th>Immunology/Transplantation</th>
<th>Insulin Action/Molecular Metabolism</th>
<th>Integrated Physiology/Obesity</th>
<th>Islet Biology/Insulin Secretion</th>
</tr>
</thead>
</table>
| 2:00 p.m.-4:00 p.m.| Symposium Evidence-Based Guidelines for Diabetes and Chronic Kidney Disease | Symposium The Expanded Scope of the Diabetes Care and Education Specialist | Symposium Screening for Gestational Diabetes — Is This Your Final Answer?  
Symposium COVID-19 and Diabetes — An Update  
Symposium Mental Health Disorders in Patients with Diabetes — A Most Challenging Mix | Symposium Health Care as a Social Justice Issue in the Diagnosis and Management of Diabetes | Symposium Innovations in Beta-Cell Replacement Therapy | Symposium Fructose Metabolism and Disease — Intestine, Microbiota, and Liver | Symposium Autonomic Nervous System (ANS) Control of Peripheral Metabolism and Metabolic Diseases | Symposium Functional Consequences of Islet Non-beta Cells |
| 4:15 p.m.-6:15 p.m.| Symposium A Primer on Diabetes Foot Management for the Primary Care Provider | Symposium The Molecular Transducers behind the Benefits of Physical Activity | Symposium SGLT2is and GLP-1RAs — Are They Worth It?  
Symposium Implementing Type 1 Diabetes Immune Intervention in Clinical Practice | Oral Presentations | Symposium Age, Sex, and Ethnicity — Impact on Type 1 Diabetes Development | Oral Presentations | Oral Presentations |
|                    |                                          | Oral Presentations |                                       |                         | Oral Presentations |                                 |                                |                                 |

**Virtual Exhibits and Poster Hall: Available throughout the Meeting**
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:15 a.m.-11:30 a.m.</td>
<td>ADA Chief Executive Officer Remarks; President, Health Care &amp; Education Address; and Outstanding Educator in Diabetes Award Lecture</td>
</tr>
<tr>
<td>11:30 a.m.-12:30 p.m.</td>
<td>Professional Interest Group Discussion on Exercise Physiology — Exercise in Post-COVID Infection — Implications for Treatment, Research, and Public Health Professional Interest Group Discussion on Nutritional Science and Metabolism — Food, Nutrition, and Insulin Actions Professional Interest Group Discussion on Clinical Centers and Programs — Here to Stay? Harnessing Telemedicine for Diabetes Care in the COVID-19 Era and Beyond Professional Interest Group Discussion on Islet Biology, Development, and Function — Rising Stars of Diabetes Research</td>
</tr>
<tr>
<td>12:30 p.m.-1:45 p.m.</td>
<td>Session Break (Take this opportunity to visit the Virtual Exhibits and Poster Hall)</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
</tr>
<tr>
<td>-------------------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| 1:45 p.m.-3:45 p.m. | Symposium The Pros and Cons of New Approaches to Prevent and Manage Hypoglycemia in Diabetes Therapies  
Oral Presentations Edwin Bierman Award Lecture  
Symposium Diabetes through a Health Equity Lens (With Richard R. Rubin Award Lecture)  
Oral Presentations  
Symposium Technology in Pregnancy — Continuous Glucose Monitoring (CGM) and Beyond  
Current Issues (1:45 p.m.-2:45 p.m.) Debate — Digital Coaching Systems for Type 2 Diabetes — Are They Worth the Cost?  
Current Issues (2:45 p.m.-3:45 p.m.) Debate — Are the Metabolic Benefits of Roux-en-Y Gastric Bypass Due to Weight Loss Alone?  
Oral Presentations |
| 4:00 p.m.-6:00 p.m. | Symposium Resolving Key Controversies in Diabetic Neuropathy  
Oral Presentations  
Symposium Carbohydrate Counting — Still Useful with New Technology?  
Symposium Obesity and Cardiovascular Disease in Type 1 Diabetes  
Symposium Debate — Joint ADA/AACC Presentation — Point-of-Care HbA1c — Should We Use It to Diagnose Diabetes?  
Oral Presentations  
Symposium Norbert Freinkel Award Lecture  
Symposium A Global Perspective on Diabetes — Bidirectional Learning for Lower- and Middle-Income and Higher-Income Countries  
Oral Presentations  
Symposium Nutrient Sensing and Macronutrient Metabolism  
Symposium NIDDK Symposium — Heterogeneity in Diabetes Mellitus — Developing a More Stratified Medical Approach from the Bench to Bedside  
Oral Presentations |
<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 a.m.-10:00 a.m.</td>
<td><strong>Symposium</strong> New Tools to Examine Diabetes-Related Kidney Disease</td>
</tr>
<tr>
<td></td>
<td><strong>Symposium</strong> Preserving Mental Health across the Lifespan of Living with Diabetes (and during COVID-19)</td>
</tr>
<tr>
<td></td>
<td><strong>Symposium</strong> Who Should Loop? Pro/Cons</td>
</tr>
<tr>
<td>10:15 a.m.-11:45 a.m.</td>
<td><strong>President, Medicine &amp; Science Address and Banting Medal for Scientific Achievement</strong></td>
</tr>
<tr>
<td>12:00 p.m.-1:00 p.m.</td>
<td><strong>Professional Interest Group Discussion on Diabetes and Cardiovascular Disease — Are We Going to Learn More from Broader Evaluations of New Glycemic Lowering Medications Beyond Cardiovascular Outcome (CVO) Trials? Is It Time to Let Go of “CVO” Trials?</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Professional Interest Group Discussion on Behavioral Medicine and Psychology — We Need More Mental Health Providers! Growing the Behavioral Diabetes Workforce</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Professional Interest Group Discussion on Diabetes Self-Management Education and Support (DSMES) — Post-Pandemic Care for Patients with Diabetes in a Diverse Population</strong></td>
</tr>
<tr>
<td>1:00 p.m.-2:00 p.m.</td>
<td><strong>Session Break (Take this opportunity to visit the Virtual Exhibits and Poster Hall)</strong></td>
</tr>
</tbody>
</table>
### DAY-AT-A-GLANCE SCHEDULE
**SUNDAY, JUNE 27, 2021 (CONTINUED)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Behavioral Medicine, Clinical Nutrition, Education, and Exercise</th>
<th>Clinical Diabetes/Therapeutics</th>
<th>Epidemiology/Genetics</th>
<th>Immunology/Transplantation</th>
<th>Insulin Action/Molecular Metabolism</th>
<th>Integrated Physiology/Obesity</th>
<th>Islet Biology/Insulin Secretion</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:15 p.m.-4:15 p.m.</td>
<td>Symposium The Importance of Triglycerides Continues to Emerge</td>
<td>Symposium (2:15 p.m.-3:15 p.m.)</td>
<td>Award Lecture (2:15 p.m.-3:00 p.m.)</td>
<td>Symposium Personalized Medicine for Immune Therapies in Type 1 Diabetes</td>
<td>Symposium Health Disparities among People with Obesity</td>
<td>Symposium All Roads Lead to Insulin</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oral Presentations</td>
<td>Efficacy and Safety of Dapagliflozin in Patients with and without Type 2 Diabetes Hospitalized with COVID-19 — Results from the DARE-19 Global Randomized Controlled Trial</td>
<td>Kelly West Award for Outstanding Achievement in Epidemiology Lecture</td>
<td></td>
<td>Oral Presentations</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Timing Is Everything — Meal and Exercise Timing and Your Circadian Clock</td>
<td>Symposium Aiming for Balance — Type 1 Diabetes and Exercise Management Perfected</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Aiming for Balance — Type 1 Diabetes and Exercise Management Perfected</td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Children with Type 2 Diabetes Are Not Just Little Adults</td>
<td>Symposium Reimagining Diabetes Care in the Virtual World</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Acute and Chronic Complications</td>
<td>Behavioral Medicine, Clinical Nutrition, Education, and Exercise</td>
<td>Clinical Diabetes/Therapeutics</td>
<td>Epidemiology/Genetics</td>
<td>Immunology/Transplantation</td>
<td>Insulin Action/Molecular Metabolism</td>
<td>Integrated Physiology/Obesity</td>
</tr>
<tr>
<td>--------------</td>
<td>---------------------------------</td>
<td>---------------------------------------------------------------</td>
<td>-------------------------------</td>
<td>-----------------------</td>
<td>--------------------------</td>
<td>-------------------------------</td>
<td>-------------------------------</td>
</tr>
<tr>
<td>8:00 a.m.-10:00 a.m.</td>
<td>Symposium Surgical Considerations in Diabetes Foot Management Oral Presentations</td>
<td>Symposium Diabetes Prevention — Addressing Implementation Challenges Oral Presentations</td>
<td>Symposium Automation and Expanded Use of Technology in the Inpatient Setting — An Update Symposium Is Continuous Glucose Monitoring (CGM) an Effective Diabetes Management Tool in Primary Care? Symposium Management of Type 1 Diabetes in Adults — 2021 Draft ADA/EASD Consensus Report Oral Presentations</td>
<td>Oral Presentations</td>
<td>Symposium Clinical and Regulatory Hurdles Facing Islet Transplantation</td>
<td>Symposium Fibrosis — At the Metabolism—Signaling Interface</td>
<td>Oral Presentations</td>
</tr>
<tr>
<td>10:10 a.m.-11:45 a.m.</td>
<td>National Scientific &amp; Health Care Achievement Awards Presentation and Outstanding Scientific Achievement Award Lecture</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00 p.m.-1:00 p.m.</td>
<td>Professional Interest Group Discussion on Diabetes Technology — Understanding the Current State of Apps for Supporting Effective Diabetes Care Professional Interest Group Discussion on Health Care Delivery and Quality Improvement — Don’t Forget to Ramp Up and Don’t Hesitate to Slow Down — Clinical Inertia in the Treatment of Diabetes Professional Interest Group Discussion on Pregnancy and Reproductive Health — First Trimester Screening for Diabetes — What Is the Best Approach?</td>
<td>Professional Interest Group Discussion on Public Health and Epidemiology — Is Diabetes a Risk Factor for Adverse Health Outcomes in Patients with COVID-19?</td>
<td>Professional Interest Group Discussion on Immunology, Immunogenetics, and Transplantation — Clinical Response Endotypes in Type 1 Diabetes</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:00 p.m.-2:00 p.m.</td>
<td>Session Break (Take this opportunity to visit the Virtual Exhibits and Poster Hall)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| 2:15 p.m.-4:15 p.m. | Symposium Neonatal Hypoglycemia — Overdiagnosed or Underestimated?  
Oral Presentations  
Roger Pecoraro Award Lecture  
Symposium Accelerating Care and Education — Digital Health and Diabetes Support — Patient and Provider Perspectives  
Symposium Joint ADA/ISPAD Symposium — General Population Screening vs. Targeted Screening for Type 1 Diabetes Risk  
Symposium Management of Atypical Diabetes Oral Presentations  
Symposium T Cells in Diabetes — Past, Present, and Future  
Symposium Interorgan Cross Talk — Metabolites, Proteins, and Extracellular Vesicles  
Symposium Environmental Exposures and Susceptibility to Obesity and Metabolic Consequences — What Are the Main Drivers? Oral Presentations | Symposium Integrated Physiology/Obesity  
Symposium Islet Biology/Insulin Secretion |  
Symposium Joint ADA/ASN Symposium — New Therapies for Kidney Protection in Diabetes Oral Presentations  
Symposium The Diabetes Digital Landscape through a Psychosocial and Behavioral Lens Oral Presentations  
Symposium (4:30 p.m.-6:55 p.m.) Results of the Glycemia Reduction Approaches in Diabetes — A Comparative Effectiveness (GRADE) Study Oral Presentations  
Symposium Imagining How Genetics Alters Risk of Diabetes Oral Presentations | Oral Presentations  
Symposium COVID-19, Diabetes, and Obesity | Symposium The Latest on Incretin/GPCR Signaling in the Islet |
<table>
<thead>
<tr>
<th>Time</th>
<th>Symposia</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 a.m.</td>
<td><strong>Symposium</strong> (9:00 a.m.-10:00 a.m.) Translating Diabetes and Kidney Disease Clinical Trial Findings into Clinical Practice</td>
</tr>
<tr>
<td>9:00 a.m.</td>
<td>Current Issues (8:00 a.m.-9:20 a.m.) Debate — Precision Nutrition — Are We There Yet?</td>
</tr>
<tr>
<td>9:00 a.m.</td>
<td><strong>Symposium</strong> (8:00 a.m.-9:30 a.m.) Next Chapter in Incretin-Based Therapies — Tirzepatide, a Novel Dual GIP/GLP-1 Receptor Agonist — Results from the First Phase 3 SURPASS Clinical Trials</td>
</tr>
<tr>
<td>10:00 a.m.</td>
<td><strong>Symposium</strong> High Dimensional Data in Epidemiologic Research — Gentle Introduction to Methods and Survey of Strengths and Limitations</td>
</tr>
<tr>
<td>10:15 a.m.</td>
<td><strong>Symposium</strong> Update on SCORED and SOLOIST Cardiovascular and Kidney Outcomes Trials</td>
</tr>
<tr>
<td>10:15 a.m.</td>
<td><strong>Symposium</strong> Insulin as a Driver of Cancer</td>
</tr>
<tr>
<td>10:15 a.m.</td>
<td><strong>Symposium</strong> The Islet and Type 1 Diabetes</td>
</tr>
</tbody>
</table>
**SCIENTIFIC PROGRAM**

**FRIDAY, JUNE 25**

11:30 a.m.-12:30 p.m.

- **The Impact of COVID-19 on Foot Care in Diabetes**
  Effects of COVID-19 on the Delivery of Diabetic Foot Care
  Brian M. Schmidt, DPM
  Utilizing Telemedicine in Diabetic Foot Care
  Laura Shin, DPM, PhD

- **Question and Discussion Period**

- **Intersection of Diabetes, Heart Failure, and Kidney Disease — Challenges and New Insights**
  Heart Failure in Diabetes — New Therapeutic Insights
  Biykem Bozkurt, MD, PhD, FHFSA, FACC, FAHA, FACP
  Diabetic Kidney Disease — What Is on the Horizon?
  Harriette Van Spall, MD, MPH
  Combination Therapy with SGLT2i and GLP-1RA in Mitigating Cardiorenal Metabolic Risk
  Vanita R. Aroda, MD

- **Question and Discussion Period**

- **Carbohydrate Intake and Its Impact on Athletics and Health — A Debate**
  High/Normal Carbohydrate Intake Optimizes Performance and Glycemia
  James P. Morton, PhD
  Low Carbohydrate Intake Optimizes Performance and Glycemia
  Dominic D’Agostino, PhD

- **Diabetes Prevention in Vulnerable Populations**
  Effects of Medicaid Coverage on the Diabetes Prevention Program in California
  O. Kenrik Duru, MD, MSHS
  U.S. State Efforts to Sustain the National Diabetes Prevention Program
  Gia E. Rutledge, MPH
  Diabetes Prevention in the Indian Health Service
  Ann Bullock, MD

- **Question and Discussion Period**

- **Could Point-of-Care Devices Prove Useful in the Diagnosis of Diabetic Neuropathy in Clinical Practice?**
  Yes
  Bruce A. Perkins, MD, MPH
  No
  Brian C. Callaghan, MD, MS

- **Executive Function in Youth with Type 1 Diabetes — Driven to Diabetes Distraction**
  Executive Functioning, Symptoms of Depression and Anxiety, Adherence, and Glycemic Control in Youth with Type 1 Diabetes
  Danny C. Duke, PhD
  Executive Functioning in Context — Risk and Protective Factors
  Eveline R. Goethals, PhD
  Work in Progress — Developmental Trajectories of Executive Function across Adolescence
  Maartje de Wit, PhD
  Clinical Strategies for Identifying Executive Function Problems and Using Diabetes Technology to Support Youth with Type 1 Diabetes
  Rachel M. Wasserman, PhD

- **COVID-19, Diabetes, and Pregnancy — The Perfect Storm?**
  Diagnosis and Management of Diabetes in Pregnancy during the COVID-19 Pandemic
  David McIntyre, MD, FRACP
  Telemedicine for Management of Diabetes in Pregnancy during COVID-19 and Beyond
  Noelia Zork, MD

- **Question and Discussion Period**

- **The Anatomy of Interdisciplinary Integration in Health Care Education**
  A Model for the Expanded Role of the Diabetes Care and Education Specialist into Clinical Diabetes Care Management
  Paul Sacks, MD
  Panel Discussion — Professional Education and Development to Drive Integration — How Do We Teach and Beyond?
  Jennifer A. LeBlanc, MS, RN, CDCES
  Nuha Ali El Sayed, MD, MMSc
  Samar Hafida, MD

- **Question and Discussion Period**

- **The Bile Acid Receptor FXR and the Microbiome**
  Probiotics and Bile Acids
  Yu-Jui Yvonne Wan, PhD
  Gut Microbiota and FXR
  Antonio Moschetta, MD, PhD
  Pharmacologic Utilization of Bile Acid-FXR Pathway to Treat Nonalcoholic Steatohepatitis
  Grace L. Guo, MBBS, PhD

- **Question and Discussion Period**

- **Dietary Modulation of Nutrient Metabolism in Cancer**
  Obesity and Cancer — A Metabolic Connection?
  Gen-sheng Feng, PhD
  Molecular Mechanisms Driving Dietary Cancer Therapy
  Christian Metallo, PhD

- **Question and Discussion Period**

- **Debate — What’s the Hubbub about Beta-Cell Hubs?**
  Hubs Are Real
  Guy A. Rutter, PhD
  Hubs Are Not Real
  Patrik Rorsman, BM, PhD, FRS, FMedSci

- **Question and Discussion Period**

12:45 p.m.-1:45 p.m.

- **We All Know What Causes Hypoglycemia, Don’t We?**
  Heterogeneity of Responses to Hypoglycemia — Lessons from Animal Models
  Candace M. Reno, PhD
  Disparity of Risk for Impaired Awareness of Hypoglycemia and Severe Hypoglycemia — Exploring the Human Situation
  Amir Mohheet, MBBS

- **Question and Discussion Period**

Speakers and presentation titles are subject to change.
• COVID-19 and Lipids — What’s the Connection?
  Plasma Lipid Changes in Response to COVID-19 Infection and Implications for Outcomes
  Kenneth Feingold, MD
  Potential Role of Lipids and Lipid Therapies (Statins, Fibrates, HDL-Raising Drugs) in Modulating COVID-19 Infections
  Alan Remaley, MD
  Question and Discussion Period

• Identifying Patients at Risk — Kidney Disease Surveillance in Diabetes
  Barriers to Kidney Disease Awareness and Testing in People with Diabetes
  Chi Chu, MD
  Geospatial Approach to Chronic Kidney Disease Surveillance in Diabetes — Identifying Disparities and Hotspots
  Xiaosong Zhang, MS
  Question and Discussion Period

• Diabetes Retinopathy Detection and Treatment in Resource-Constrained Areas
  Implementing a Diabetes Retinopathy Referral Network and Treatment in Peru
  Omar Salamanca, MD
  Implementing a Diabetes Retinopathy Research Network and Treatment in Latin America
  J. Fernando Arevalo, MD, PhD, FACS
  Question and Discussion Period

• Diabetes “Diets” since the Discovery of Insulin — Looking Back, Then to the Future
  1921 to 1970s — Starvation Diets to the Exchange System
  Melinda D. Maryniuk, MEd, RDN, CDCES
  1980s to 2021 — Prescribed Macronutrient Percentages to Person-Centered Approaches and Beyond
  Hope Warshaw, MMSc, RD, CDCES
  Question and Discussion Period

• Are We There Yet? Initiating SGLT2 Inhibitors and/or GLP-1RAs in the Inpatient Cardiovascular Setting
  Time to Consider Initiating SGLT2 Inhibitors and/or GLP-1RAs in the Inpatient Cardiovascular Care Setting — And Here’s How
  Sandeep Das, MD, MPH
  Caution before Universally Recommending Initiation of SGLT2 Inhibitors and/or GLP-1RAs in the Inpatient Cardiovascular Care Setting
  Jennifer B. Green, MD
  Question and Discussion Period

• COVID-19 and Beyond — Viruses in Pediatric Diabetes
  Epidemiology of COVID-19 and Pediatric Diabetes — New-Onset/Diabetic Ketoacidosis
  Mary Pat Gallagher, MD
  What’s New in Type 1 Diabetes Epidemiology? A View from the Virology World
  Kendra Veik, PhD, MPH
  Behavioral Interventions for Pediatric Diabetes during COVID-19
  Carrie Tully, PhD
  Question and Discussion Period

• Diabetes and the Brain across the Lifespan — Neurocognitive Deficits and Decline
  Prevention of Cognitive Impairment in Diabetes
  Anna Marseglia, PhD
  Diabetes and the Developing Brain
  Fergus Cameron, FRACP, MD
  Question and Discussion Period

• Debate — Should Immune Intervention Trials Occur during the COVID-19 Pandemic?
  For — Type 1 Diabetes Immune Intervention Trials during COVID-19
  Carla Greenbaum, MD
  Against — Type 1 Diabetes Immune Intervention Trials during COVID-19
  Adriana Weinberg, MD
  Question and Discussion Period

• Debate — Intergenerational Transmission of Obesity — Focus on the Womb or the Home?
  Introduction
  Amy E. Rothberg, MD, PhD, DABOM Womb
  Peter Gluckman, ONZ, KNZM, FRSNZ, FMedSci, FRSM Home
  Julie Lumeng, MD
  Question and Discussion Period

• Influence of Social Inequalities and Social Stress on Metabolic Health
  Social Determinants of Metabolic Health — Evidence from Human Populations
  Mika Kivimäki, PhD
  Social Determinants of Metabolic Health — Evidence from Animal Models
  Carol Shively, PhD
  Question and Discussion Period

2:00 p.m.-4:00 p.m.

• Evidence-Based Guidelines for Diabetes and Chronic Kidney Disease
  Living with Diabetes and Chronic Kidney Disease
  Tami Sadusky, BS, MBA
  New Kidney Disease Improving Global Outcomes (KDIGO) Guideline for Management of Diabetes in Chronic Kidney Disease
  Luiza Caramori, MD, MSc, PhD
  How Do the ADA, EASD, and KDIGO Guidelines for Diabetes and Chronic Kidney Disease Compare?
  John B. Buse, MD, PhD
  How Will New Clinical Trials Affect Evidence-Based Care for People with Diabetes and Kidney Disease?
  Peter Rossing, MD, DMSc
  Question and Discussion Period
• The Expanded Scope of the Diabetes Care and Education Specialist
  Outcomes of Digital Health — Lessons Learned
  Nicole Berelos, PhD, MPH, MSCP, CDCES
  Preparing Diabetes Care and Education Specialists in 2021 and Beyond
  Jane K. Dickinson, RN, PhD, CDCES
  Pharmacy — Increase Access to Diabetes Self-Management and Support Services on the Front Lines
  Staci-Marie Norman, PharmD, CDE
  Integrating Mental Health Strategies into Practice
  Susan Guzman, PhD

• Screening for Gestational Diabetes — Is This Your Final Answer?
  Gestational Diabetes Mellitus Screening Strategies — Answers from Randomized Controlled Trials
  Christina M. Scifres, MD
  Gestational Diabetes Mellitus Screening Strategies — Can We Get Pragmatic Answers?
  Teresa Hillier, MD, MS
  Preanalytical Blood Samples Handling during Gestational Diabetes Testing — How Much Does It Change Results?
  Christopher J. Nolan, PhD, FRACP
  Should We Have Different Gestational Diabetes Mellitus Screening Strategies Depending on Prepregnancy Body Mass Index and Other Risk Factors?
  Dorte Møller Jensen, MD, PhD
  Question and Discussion Period

• COVID-19 and Diabetes — An Update
  Role of Hyperglycemia on COVID-19 Outcomes
  Alberto Coppelii, MD
  COVID-19 and New-Onset Diabetes — Unmasking Type 2 Diabetes, Triggering Autoimmunity, or Both?
  Francesco Rubinii, MD
  Managing and Preventing Diabetic Ketoacidosis during the COVID-19 Pandemic
  Bruce W. Bode, MD
  Remote Monitoring of COVID-19 Patients via Continuous Glucose Monitoring
  Francisco J. Pasquell, MD, MPH

• Mental Health Disorders in Patients with Diabetes — A Most Challenging Mix
  Depression in Patients with Diabetes — Prevalence, Impact on Glycemic Control, and Strategies for Comanagement
  Jeffrey S. Gonzalez, PhD
  Challenges in Managing Diabetes in Patients with Psychotic Disorders
  Lydia Chwastiak, MD, MPH
  Practical Approaches for Eating Disorders in Diabetes
  Ann E. Goebel-Fabbri, PhD
  Anxiety Disorders and Diabetes — What Is the Relationship?
  Tina Drossos, PhD

• Health Care as a Social Justice Issue in the Diagnosis and Management of Diabetes
  Ten Years of the Affordable Care Act — Implications for Diabetes Diagnosis and Management
  J. Frank Wharam, MD, MPH
  Diabetes, Social Vulnerability, and Health Outcomes
  Shivani Agarwal, MD, MPH
  Disentangling Social and Biological Risk Factors from a Social Epidemiology Perspective
  Shakira F. Suglia, ScD, MS
  Racism, Discrimination, and Health Care in Diabetes
  TBD
  Innovation in Health Care Financing to Mitigate Disparities in Diabetes
  Monica E. Peek, MD, MPH, MSc
  Question and Discussion Period

• Innovations in Beta-Cell Replacement Therapy
  Advances from the JDRF Consortium
  Esther Latres, PhD
  Immunomodulatory Strategies in Beta-Cell Transplantation
  James M. Gardner, MD, PhD
  Progress in Stem Cell-Derived Islets
  Quinn R. Peterson, PhD

• Fructose Metabolism and Disease — Intestine, Microbiota, and Liver
  Microbial Fructose Fermentation and Metabolic Disease
  Kathryn E. Wellen, PhD
  Just Passing Through — Pre- and Postportal Fructose Metabolism
  Cholsoon Jang, PhD
  Fructose — Fueled the Fire of Tissue Injury in Nonalcoholic Fatty Liver Disease
  Michael Karin, PhD
  Poised for Trouble — The Challenge Posed by Excess Fructose
  Mark A. Herman, MD

• Autonomic Nervous System (ANS) Control of Peripheral Metabolism and Metabolic Diseases
  Sex Differences in the ANS Control of Energy Expenditure
  Stephanie Correa, PhD
  Sympathetic Neuroimmunity in Obesity
  Ana Domingos, PhD
  Striatal Dopamine Controls Hepatic Glucose Production via the ANS
  Susanne E. La Fleur, PhD
  ANS Control of Adipose Tissue Function
  Heike Muenzberg-Gruening, PhD

• Functional Consequences of Islet Non-beta Cells
  Arginine Vasopressin (AVP) Regulation of Glucagon Secretion
  Linford J.B. Briant, PhD
  Metabolic Specialization of Alpha Cells and How Glucose Regulates Glucagon Secretion
  Jakob G. Knudsen, PhD
  Epsilon Cells
  Jenny Tong, MD, MPH
  Delta-Cell Regulation of Ilet Hormone Secretion and Beta-Cell Replication
  Vincent Poitout, DVM, PhD

4:15 p.m.-6:15 p.m.

• A Primer on Diabetes Foot Management for the Primary Care Provider
  Why Safety, Quality, and Value Matter in the Management of the Diabetic Foot
  Priti Lakhani, DPM
  The Three-Minute Diabetes Foot Exam for the Primary Care Provider
  John D. Miller, DPM, DABFAS
  How to Make the Multispecialty Team Approach Work for Your Patients with Diabetes
  Rachel H. Albright, DPM, MPH
ADVANCE PROGRAM

- The Molecular Transducers behind the Benefits of Physical Activity
  MoTrPAC — Overview of Research on Molecular Transducers of Physical Activity
  Wendy M. Kohrt, PhD
  Preliminary Animal Studies — Molecular Responses to Acute Exercise and Training
  Karyn A. Esser, PhD
  Human Clinical Studies — Molecular Responses to Acute Exercise and Training
  Bret H. Goodpaster, PhD
  The "Omeics" Approach — Responses to Acute Exercise and Training
  Aaron N. Winn, PhD
  SGLT2is and GLP-1RAs — Equity and Benefits
  Hui Shao, MD, PhD
  SGLT2is and GLP-1RAs — What Are the Costs and Cost-Effectiveness?
  Jason Alexander, MD
  Type 1 Diabetes Development: Age, Sex, and Ethnicity — Impact on Type 1 Diabetes Development
  Elizabeth J. Mayer-Davis, PhD
  Type 1 Diabetes Incidence by Age and Ethnicity
  Elizabeth J. Mayer-Davis, PhD
  Type 1 Diabetes Genetic Risk Score by Ancestry
  Maria Jose Redondo, MD, PhD, MPH
  Type 1 Diabetes Immunopathology across Ancestries
  John Kaddis, PhD
  Panel Discussion — The Influence of Age, Sex, and Ethnicity on Type 1 Diabetes
  Elizabeth J. Mayer-Davis, PhD
  Maria Jose Redondo, MD, PhD, MPH
  John Kaddis, PhD
  When Time Matters — The Influence of Time-Restricted Feeding
  Timing of Food Intake and Fasting — Circadian Rhythms and Biological Mechanisms That Mediate Health Benefits
  Dorothy D. Sears, PhD
  Metabolic Response to Time-Restricted Feeding
  Amandine Chaix, PhD
  Impact of Intermittent Fasting on Health, Aging, and Disease
  Leonie Heilbronn, PhD
  Drug Metabolism and Timing
  Manjunath Pai, PharmD
  How and Why Would Time-Restricted Feeding Lead to Weight Loss in Humans? Results of Clinical Trials and Practical Considerations
  Courtney M. Peterson, PhD, MSc, MA, MS
  Question and Discussion Period

- Oral Presentations

SATURDAY, JUNE 26

8:00 a.m.-10:00 a.m.

- Practice-Changing Trials in Heart Failure and Kidney Disease with SGLT2 Inhibitors
  Landmark Trials in Heart Failure
  Landmark Trials in Heart Failure — DAPA-HF and EMPEROR-Reduced — Do We Have All the Answers for SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction?
  Carolyn S.P. Lam, MBBS, PhD
  Landmark Trials in Heart Failure — DELIVER and EMPEROR-Preserved — Will SGLT2 Inhibitors Succeed in Heart Failure with Preserved Ejection Fraction?
  Muthiah Vaduganathan, MD, MPH
  Question and Discussion Period

- Landmark Trials in Kidney Disease
  Landmark Trials in Kidney Disease — CREDENCE — Lessons Learned from the First Trial in Nearly Two Decades to Improve Cardiac Outcomes in Diabetic Kidney Disease
  Brendon L. Neuen, MBBS (Hons), MSc
  Landmark Trials in Kidney Disease — DAPA-CKD — Extending the Benefits of SGLT2 Inhibition to and beyond Diabetic Kidney Disease
  David C. Wheeler, MD
  Question and Discussion Period

- Making Physical Activity Accessible and Doable for Everyone
  Home-Based Exercise and Other Strategies to Remove Barriers to Physical Activity
  Matthew Cocks, PhD
  Reducing and Breaking Up Sitting Time — Does This Work?
  David Dunstan, PhD
  Aiming High — How Feasible Is High-Intensity or Interval Training for Everyone?
  Jonathan P. Little, PhD
  How Can We Get Everyone Active?
  Stop Telling, Start Listening
  Mary Jung, PhD

- ADA Education Recognition Program Symposium — VHA and DoD Virtual Diabetes Self-Management Training (DSMT) — A Novel, Learner-Centered, Avatar-to-Avatar Remote Alternative for Providing Remote Certified Diabetes Education
  DSMT in the Virtual World — A Paradigm Shift for Diabetes Education?
  Brian V. Burke, MD, FACP
  VHA’s Virtual DSMT — Training the Trainer for Virtual DSMT
  Mary M. Julius, RDN, LD, CDCES
  VA/DoD Virtual DSMT — Population Served and the Patient Experience
  Stephanie De Leon Ansley, MS, RD, CSSD, LD, CDCES
  The Nuts and Bolts of Building the VA Virtual Medical Center
  Brian James, MEd

- “STEP” against Obesity — Once-Weekly Semaglutide 2.4 mg Clinical Development Program for Weight Management
  Welcome and Introduction
  Lee M. Kaplan, MD, PhD
  From the Mechanism of Action of Semaglutide 2.4 mg to the STEP Program
  Melanie J. Davies, CBE, MB, ChB, MD, FRCP, FRCGP, FMedSci
  Results from the STEP Trials in People with Obesity
  Robert F. Kushner, MD
  Cardiometabolic Outcomes in People with Prediabetes and Type 2 Diabetes
  John Wilding, DM, FRCP
  Clinical Implications of Semaglutide for Obesity Care
  Lee M. Kaplan, MD, PhD
Panel Discussion
Lee M. Kaplan, MD, PhD
Melanie J. Davies, CBE, MB, ChB, MD, FRCP, FRCGP, FMedSci
Robert F. Kushner, MD
John Wilding, DM, FRCP

• Including Social Determinants of Health in Diabetes Care
  Effects of Food Insecurity
  Seth A. Berkowitz, MD, MPH
  Effects of Housing Insecurity
  Margot Kushel, MD
  Effects of Neighborhood and Built Environment
  Brittany L. Smalls, PhD, MHSA
  Effects of Structural Violence
  Janet Page-Reeves, PhD

• Diabetes and Brain Health
  Brain Changes in Type 2 Diabetes
  Geert Jan Biessels, MD, PhD
  Cognitive Decline and Dementia in Diabetes
  Florin Despa, PhD
  Approaches to Prevention and Treatment of Brain Consequences of Diabetes
  Jose A. Luchsinger, MD, MPH

• Systemic Racism and Disparities in Pediatric Diabetes Management
  Disparities in Pediatric Diabetes Treatment
  Terri H. Lipman, PhD, CRNP
  The State of Disparities in Pediatric Diabetes Care
  Ananta Addala, DO, MPH
  ECHO-Diabetes — Delivering Care to the Underserved
  Ashby F. Walker, PhD
  Advocacy as a Means to Rebuild Systems and Improve Outcomes
  Andrea Gerard Gonzalez, MD

• ADA Diabetes Care Symposium — Learning to Minimize Risks for People with Diabetes in the COVID-19 Pandemic
  Diabetes and COVID-19 at 18 Months — Trouble Ahead, Trouble Behind
  Edward W. Gregg, PhD
  COVID-19 and Type 1 Diabetes — Maintaining Control and Addressing Concerns
  Linda DiMeglio, MD, MPH
  Presentation of Profiles in Progress Awards
  Matthew C. Riddle, MD
  Obesity, Inflammation, Hyperglycemia, and Insulin in COVID-19
  Paresh Dandona, MD, PhD, FRCP, FACC, FACC

• The Immune-Metabolism Interface
  Metabolic Conditioning of Skeletal Muscle to Endurance Exercise
  Chih-Hao Lee, PhD
  Immune-Adipose Cross Talk via Nicotinic Acetylcholine Receptor Signaling
  Jun Wu, PhD
  Glucose Links SARS-CoV-2 Infection to Monocyte Response in Diabetes
  Jean-François Gautier, MD
  Meteorin-Like 2 Mediates Immune Regulation of Muscle Repair
  James White, PhD

• Polycystic Ovary Syndrome (PCOS) — Towards Personalized Medicine — Advances in PCOS Diagnosis and Care
  Functional Analysis of PCOS Candidate Gene
  Jan McAllister, PhD
  Is Exercise in PCOS the Same?
  Erik A. Richter, MD, DMSci
  New Approaches for Treatment of PCOS — GLP-1 or DPP-4?
  Karen Elkind-Hirsch, MS, PhD
  Consideration of Mood Changes When Treating Metabolic Health in PCOS
  Anuja Dokras, MD, PhD

• Joint ADA/Chinese Diabetes Society Symposium — Novel Mechanisms and Targets
  Adipose Cell-Cell Signaling in Obesity and Inflammation
  Melian Liu, PhD
  Amino Acid Regulation and Lipid Metabolism
  Feifan Guo, PhD
  Gestational Diabetes in China and the Effect of Intrauterine Environment
  Miao Yu, MD, PhD
  B-Cell Function and Diabetes
  Xiaomu Li, MD, PhD

• Beta-Cell Senescence/Stress
  Insulin Misfolding Activates Beta-Cell ER-Phagy
  Billy Tsai, PhD
  Beta-Cell Senescence in Type 1 Diabetes
  Peter Thompson, MSc, PhD
  Humanized MaTa Mouse — A Model of Senescence
  Emily May Walker, PhD
  Comprehensive Proteomics Analysis of Stressed Human Islets
  Ernesto Nakayasu, PhD, BS

• Oral Presentations
  10:15 a.m.-11:30 a.m.
  • ADA Chief Executive Officer Remarks
    Tracey D. Brown, MBA, BChE
  • President, Health Care & Education Address
    Cynthia E. Muñoz, PhD, MPH
  • Outstanding Educator in Diabetes Award Lecture
    Denise Charron-Prochownik, PhD, CPNP
11:30 a.m.-12:30 p.m.

- **Professional Interest Group Discussion on Exercise Physiology** — Exercise in Post-COVID Infection — Implications for Treatment, Research, and Public Health
  
  **Introduction**
  Ian R. Lanza, PhD

  **Parameters for Post-COVID Participant Enrollment and Participation in MoTrPAC**
  Wendy M. Kohrt, PhD

  **Current Research on Exercise Rehabilitation for Post-COVID Syndrome**
  Gordon McGregor, PhD

  **Roundtable Discussion**
  Jane E.B. Reusch, MD
  Sheri Colberg, PhD, FACSM
  Ian R. Lanza, PhD

- **Professional Interest Group Discussion on Nutritional Science and Metabolism** — Food, Nutrition, and Insulin Actions
  
  **Introduction**
  Guoxun Chen, PhD

  **Lipotoxicity or Glucotoxicity? Roles of Lipids and Carbohydrates in Insulin Resistance**
  Philipp E. Scherer, PhD

  **Lipids and Carbohydrates — Food Sources, Quality, Costs, and Beyond**
  Jackie L. Boucher, MS, RDN

  **Question and Discussion Period**

- **Women’s Interprofessional Network of the ADA (WIN ADA) — Long-Term Professional Impact of COVID-19**
  
  **Introduction**
  Brenda Montgomery, RN, MSHS, CDE
  Darleen A. Sandoval, PhD

  **The Impact of the COVID-19 Pandemic on Academia and Clinical Trials**
  Laura C. Alonso, MD
  Sharon Edelstein, ScM

  **Long-Term Professional Impact of COVID-19 on Clinical Care**
  Cynthia E. Muñoz, PhD, MPH
  Jennifer Baldwin, BSN, RN, CPN, CDCES

  **The Women’s Leadership Gap in Diabetes — History and Data from the COVID-19 Era**
  Jessica L. Dunne, PhD
  Amanda Posgai, PhD

- **Professional Interest Group Discussion on Clinical Centers and Programs** — Here to Stay? Harnessing Telemedicine for Diabetes Care in the COVID-19 Era and Beyond
  
  **Introduction**
  Edward Chao, DO

  **Outpatient Opportunities**
  Michelle L. Griffith, MD

  **Inpatient Insights**
  Robert J. Rushakoff, MD

  **The Future Is Now**
  TBD

  **Question and Discussion Period**

12:30 p.m.-1:45 p.m.

- **Session Break (Take this opportunity to visit the Virtual Exhibits and Poster Hall)**

1:45 p.m.-3:45 p.m.

- **The Pros and Cons of New Approaches to Prevent and Manage Hypoglycemia in Diabetes Therapies**
  
  **Smart Insulins to Reduce Hypoglycemia Risk**
  Danny Hung-Chieh Chou, PhD

  **Glucagon in the Prevention and Treatment of Hypoglycemia**
  Jennifer Sherr, MD, PhD

  **The Limitations of Hybrid Closed-Loop Insulin Delivery Systems in Hypoglycemia Avoidance**
  Steven J. Russell, MD, PhD

  **Psychological Hurdles to Optimal Hypoglycemia Management**
  Nicole de Zoysa, DClin, Psych

- **Professional Interest Group Discussion on Islet Biology, Development, and Function** — Rising Stars of Diabetes Research
  
  **Information not available at the time of publication.**

- **Technology in Pregnancy** — Continuous Glucose Monitoring (CGM) and Beyond
  
  **CGM in Pregnancy — Real-World Data in Type 1 Pregnancy**
  Kerstin Berntorp, MD, PhD

  **Analyzing Temporal Profiles from CGM in Pregnancy — Importance for Clinical Outcomes**
  Eleanor M. Scott, BM, BS, MD, FRCP

  **CGM and Biomarkers for Prediction of Pregnancy Outcomes — Which Is Better?**
  Claire L. Meek, MB, ChB, MRCP, FRCPath, PhD

  **Use of CGM in Women with Gestational Diabetes Mellitus**
  Dessi Zaharieva, PhD

  **Performance of CGM — Is It Reliable?**
  Carol J. Levy, MD, CDE

  **Question and Discussion Period**

- **Debate — Digital Coaching Systems for Type 2 Diabetes — Are They Worth the Cost?**
  
  **Yes**
  Anne L. Peters, MD

  **No**
  Kasia J. Lipska, MD, MHS, BS

  **Rebuttal**
  Anne L. Peters, MD

  **Rebuttal**
  Kasia J. Lipska, MD, MHS, BS
• Debate — Are the Metabolic Benefits of Roux-en-Y Gastric Bypass Due to Weight Loss Alone?
  Yes, the Metabolic Benefits of Roux-en-Y Gastric Bypass Are Due to Weight Loss Alone
  Samuel Klein, MD
  No, the Metabolic Benefits of Roux-en-Y Gastric Bypass Extend Beyond the Weight Loss Effect
  Blandine Laferrère, MD, PhD
  Rebuttal
  Samuel Klein, MD
  Rebuttal
  Blandine Laferrère, MD, PhD

• Beyond Genome-Wide Association Studies — Understanding the Function of Variants Associated with Diabetes
  The Human Pancreas Analysis Program (HPAP) — From Massive Data to New Insights
  Klaus H. Kaestner, PhD, MS
  From Discovery to Function in Obesity
  Inês Barroso, PhD
  Exploring Enhancer-Promoter Interactions in Human Pancreas Cells
  H. Efsun Arda, PhD
  Decoding Variant Effects on (Patho-)physiologic Cellular Responses
  Michael L. Stitzel, PhD

• Current Role of Pancreas Transplantation in the Treatment of Diabetes
  New Indications for Pancreas Transplantation — An Overview
  Ty B. Dunn, MD
  Pancreas Transplantation for Type 2 Diabetes
  Jon S. Odorico, MD, FACS
  Emerging Trends and Controversies in Pancreas Transplantation
  Eelco J.P. de Koning, MD, PhD

• Insulin at Its 100th Birthday
  Historical Overview
  David M. Harlan, MD
  Insulin Secretion
  Peter Arvan, MD, PhD
  What We Know about How Insulin Works — 100 Years Later
  C. Ronald Kahn, MD
  The Future of Insulin as a Therapy
  Michael A. Weiss, MD, PhD, MBA

• ES-Derived Beta Cells — From Disease Modeling to Therapeutics
  Generation of Beta Cells from Stem Cells — State of the Art
  Jeffrey R. Millman, PhD
  Successes and Challenges for Stem Cell Therapy in Diabetes
  Julie B. Sneddon, PhD
  Noncoding Disease Modifier Effects on Beta Cells Informed from Patient Cell Lines
  Paul Gadue, PhD
  Using Patient-Derived Stem Cells to Study the Cell Biology and Function of Human Endocrine Cells in Nutrient Homeostasis
  James Wells, PhD

• Oral Presentations
  • Edwin Bierman Award Lecture
    Russell Debose-Boyd, PhD
  4:00 p.m.-6:00 p.m.
  • Resolving Key Controversies in Diabetic Neuropathy
    Getting Lost in Translation — The Murky Path from Curing Neuropathy in Diabetic Rodents to Success in Clinical Trials
    Nigel A. Calcutt, PhD
    Statin Treatment and Risk of Neuropathy in Diabetes — Friend or Foe?
    Fabiana Picconi, MD
    How Does Neuropathy Affect the Risk of Falls and Fractures?
    Karolina S. Kahn, MD, PhD
    Social and Psychological Determinants of Health and Impact on Peripheral and Autonomic Neuropathy
    Kara R. Mizokami-Stout, MD

• Carbohydrate Counting — Still Useful with New Technology?
  Real-World Perspective on Carbohydrate Counting for Bolus Insulin Decision-Making
  Becky Sulik, RDN, LD, CDE
  From Carbohydrate-Centricity to Factoring in Protein, Fat, Fiber, Glycemic Index, and More to Determine and Teach Bolus Insulin Dosing
  Kirstine Bell, APD, CDE, PhD
  Using Continuous Glucose Monitoring Data to Optimize Food Intake and Glycemic Management
  Holly Willis, PhD, RDN, LD
  The Future of Diabetes Nutrition Management Using New Insulin Delivery Technology
  Bruce A. Buckingham, MD

• Obesity and Cardiovascular Disease in Type 1 Diabetes
  Epidemiology of Obesity and Cardiovascular Comorbidities in Type 1 Diabetes
  Tina Costacou, PhD
  The Current Management of Cardiovascular Risk Factors in Type 1 Diabetes
  Yehuda Handelsman, MD
  Debate — Should Type 2 Diabetes Medications with Proven Cardiovascular Benefits Be Used in Type 1 Diabetes to Prevent Atherosclerotic Cardiovascular Disease?
  No
  Vivian Fonseca, MD
  Yes
  Sophia Zoungas, MBBS (Hons), PhD, FRACP
  Question and Discussion Period

• Debate — Joint ADA/AACC Presentation — Point-of-Care HbA1c — Should We Use It to Diagnose Diabetes?
  Point-of-Care HbA1c — Methods and Performance
  Randie R. Little, PhD
  We Should Use Point-of-Care HbA1c to Diagnose Diabetes
  Jay H. Shubrook, DO, FACOFP, FAAFP
  We Should Not Use Point-of-Care HbA1c to Diagnose Diabetes
  David B. Sacks, MB, ChB
  Question and Discussion Period

• A Global Perspective on Diabetes — Bidirectional Learning for Lower- and Middle-Income and Higher-Income Countries
  A Global Perspective on Food and Nutrition Policies and Diabetes
  Lindsay M. Jaacks, PhD
  A Global Perspective on Cardiovascular Disease Complications in Diabetes
  Kavita Singh, PhD
  A Global Perspective on the Increasing Prevalence of Diabetes and the Role of the Environment
  Frank Hu, MD, PhD
  A Global Perspective on Prevention of Diabetic Ketoacidosis at Type 1 Diabetes Diagnosis
  Pradeep A. Praveen, MPH, PhD
Nutrient Sensing and Macronutrient Metabolism
Amino Acid Metabolism as a Major Sex-Discriminating Factor in the Liver
Adriana Maggi, PhD
Liver FGF21 as an Endocrine Signal of Protein and Amino Acid Restriction
Christopher Morrison, PhD
Brain Amino Acid Sensing and Appetite Control
Clemence Blouet, PhD
Targeting Hepatocyte Carbohydrate Transport to Mimic Fasting and Calorie Restriction
Brian DeBosch, MD, PhD

NIDDK Symposium — Heterogeneity in Diabetes Mellitus — Developing a More Stratified Medical Approach from the Bench to Bedside

Welcome Remarks from the NIDDK Director
TBD

Introduction of Beta-Cell Biology Presentations
Olivier Blondel, PhD
Beta-Cell Biology and Implications for the Bedside
Preclinical Molecular Markers of Beta-Cell Stress in Type 1 Diabetes/Molecular Mechanisms Contributing to 8-Cell Dysfunction and the Development of Diabetes
Emily K. Sims, MD, MS
Identifying Endogenous Modulators of 8-Cell Function for Potential Treatment
Emilyn Alejandro, PhD
Mapping the Association of Beta-Cell Longevity and Cell Senescence in Diabetes Mellitus
Rafael Arrojo e Drigo, PhD
Introduction of Clinical Research Presentations
Miranda Broadney, MD, MPH

Gene-Driven Physiology and Population Heterogeneity in Management of Glucose Metabolism
Leveraging Genomics to Understand the Physiology of Hyperglycemia in Pregnancy
Camille E. Powe, MD
GCK-MODY Management and Outcomes during Pregnancy
Rochelle N. Naylor, MD
The Role of Adrenal Hormones in Type 2 Diabetes
Joshua J. Joseph, MD, MPH, FAHA
Final Questions/Session Wrap-up
Olivier Blondel, PhD
Miranda Broadney, MD, MPH

Oral Presentations
Norbert Freinkel Award Lecture
Denice Feig, MD, MSc, FRCP

Who Should Loop? Pro/Cons
Nuts and Bolts of “Looping” in 2021 TBD
Lived Experience
Anna Norton, MS
Looping Is for Everyone
Dana Lewis, DO
DIY — Provider Concerns, Approaches, and the Future
David M. Maahs, MD, PhD

Matchmaker, Matchmaker, Make Me a Match — Selecting Glucose-Lowering Combinations for Type 2 Diabetes Mellitus
Incretins and SGLT2 Inhibitors
Ralph A. DeFronzo, MD
Insulin and SGLT2 Inhibitors
Chantal Mathieu, MD, PhD
Insulin and GLP-1RAs
Tina Vilsbøll, MD, DMSc
Dual Agonists
David D’Alessio, MD

Emerging Paradigms of Uncoupled Bioenergetics in Metabolic Disease
UCP1-Independent Thermogenesis via Ca2+ Futhile Cycling
Shingo Kajimura, PhD
Noncanonical Thermogenesis via the Creatine Cycle
Bruce M. Spiegelman, PhD
Skeletal Muscle Thermogenesis and Energy Balance
Muthu Periasamy, PhD
A New Generation of Small Molecule Uncouplers
Gerald I. Shulman, MD, PhD, MACP, MACE

ADA Diabetes Symposium — New Turf for the Other Incretin — GIP Signaling in the Brain and Effects on Food Intake and Energy Balance
Interactions of GIP and Leptin in the Regulation of Energy Balance
Tune H. Pers, PhD
GIP in the Regulation of Satiety and Nausea
Matthew R. Hayes, PhD

Oral Presentations
8:00 a.m.-10:00 a.m.
New Tools to Examine Diabetes-Related Kidney Disease
Is Kidney Disease the Same in Type 1 and Type 2 Diabetes? Intrarenal Hemodynamics, Kidney Energetics, and Biomarkers
Yulia Lytvyn, PhD
The Expanding Role of MRI, PET, and NMR Imaging in Clinical Diabetic Kidney Disease Research
Petter Bjornstad, MD
Research Kidney Biopsies — Now More Important Than Ever!
Laura Barisoni, MD
Putting It All Together — Precision Medicine Gets Precise
Jonathan Himmelfarb, MD
Preserving Mental Health across the Lifespan of Living with Diabetes (and during COVID-19)
Supporting Families of Young Children with Diabetes — The Preschool and Early Childhood Years
Randi Streisand, PhD
Adolescents and Young Adults — Managing the Co-occurring Life Challenges (and Diabetes)
Jessica Pierce, PhD
Navigating Pregnancy and the Psychosocial Challenges of Diabetes
Maisa N. Feghali, MD, MSCR
The Unique Challenges of Diabetes, Mental Health, and the Elderly
David G. Marrero, PhD

Speakers and presentation titles are subject to change.
10:15 a.m.-11:45 a.m.
• President, Medicine & Science Address
  Ruth S. Weinstock, MD, PhD

• Banting Medal for Scientific Achievement
  Jens J. Holst, MD, DMSc

12:00 p.m.-1:00 p.m.
• Professional Interest Group Discussion on Diabetes and Cardiovascular Disease — Are We Going to Learn More from Broader Evaluations of New Glycemic Lowering Medications Beyond Cardiovascular Outcome (CVO) Trials? Is It Time to Let Go of “CVO” Trials?
  Introduction
  Neda Rasouli, MD
  Lisa Yanoff, MD
  Pro/Yes
  TBD
  Con/No
  Marc P. Bonaca, MD, MPH
  Question and Discussion
  Neda Rasouli, MD
  Lisa Yanoff, MD

• Professional Interest Group Discussion on Eye Health — Ocular Health Care by Telehealth and Artificial Intelligence (AI)
  Introduction
  George L. King, MD
  The Use of AI in the Diagnosis of Diabetic Retinopathy
  Michael D. Abràmoff, MD, PhD
  Lloyd Paul Aiello, MD, PhD
  Telehealth in Ocular Care for Diabetic Retinopathy before and after COVID-19
  Bobek S. Modjtabahdi, MD

• Professional Interest Group Discussion on Behavioral Medicine and Psychology — We Need More Mental Health Providers! Growing the Behavioral Diabetes Workforce
  Introduction
  TBD
  Progress from the ADA-APA Mental Health Provider Training Program
  Marisa E. Hilliard, PhD
  Training Mental Health Providers to Staff Diabetes Clinics
  TBD
  CDCES Perspective on Providing Mental Health Care
  Laurel H. Messer, PhD, RN, CDCES
  Question and Discussion Period

• Professional Interest Group Discussion on Diabetes Self-Management Education and Support (DSMES) — Post-Pandemic Care for Patients with Diabetes in a Diverse Population
  Introduction
  Clipper F. Young, PharmD, MPH, CDCES, BC-ADM, BCGP
  Delivering DSMES Post-Pandemic — Addressing Health Equity in a Diverse Population
  Ashby F. Walker, PhD
  Lessons Learned from COVID-19 — What Have CDCESs Done to Maintain the Delivery of DSMES to a Diverse Population?
  Beverly Thomassian, RN, MPH, CDCES, BC-ADM
  Question and Discussion Period

• Professional Interest Group Discussion on Diabetes in Youth — Identification and Management of Prediabetes in Youth — Pros vs. Cons
  Introduction
  Jean M. Lawrence, ScD, MPH, MSA
  Session Overview
  Silva A. Arslanian, MD
  Pros
  Tamara S. Hannon, MD, MS
  Cons
  Philip Zeitler, MD, PhD

1:00 p.m.-2:00 p.m.
• Session Break (Take this opportunity to visit the Virtual Exhibits and Poster Hall)

2:15 p.m.-4:15 p.m.
• The Importance of Triglycerides Continues to Emerge
  Insights on the Causative Role of Elevated Triglyceride Levels from Mendelian Randomization Studies
  Brian A. Ference, MD, MPhil, MSc, FACC, FESC
  Is There a Role for Fibrates and n-3 Fatty Acids Other than Icosapent Ethyl in the Treatment of Hypertriglyceridemia?
  Lisa Tannock, MD
  New Insights into Plasma Triglyceride Processing by the GPIHBP1–LPL Complex
  Stephen G. Young, MD

81ST VIRTUAL SCIENTIFIC SESSIONS | JUNE 25-29, 2021 | #ADA2021

Speakers and presentation titles are subject to change.
• Reimagining Diabetes Care in the Virtual World
  Virtual Diabetes Prevention
  Tannaz Moin, MD, MBA, MSHS
  Virtual Diabetes Group Visits
  Arshiya A. Baig, MD, MPH
  Leveraging Information Technology to Provide Diabetes Care Virtually
  Mary Reed, DrPH
  Equity and Reimbursement of Telemedicine
  Sachin D. Shah, MD

• Children with Type 2 Diabetes Are Not Just Little Adults
  Epidemiology of Type 2 Diabetes — SEARCH Update
  Angela D. Liese, PhD, MPH, FACE, FAHA
  Pathophysiology of Pediatric Type 2 Diabetes — RISE and Running to the Future
  Tamara S. Hannon, MD
  Beyond Metformin — Novel Treatment Options for Type 2 Diabetes in Children/Youth
  Elvira M. Isganaitis, MD, MPH
  The Future of Pediatric Type 2 Diabetes
  Sonia Caprio, MD

• Kelly West Award for Outstanding Achievement in Epidemiology Lecture
  Nicholas Wareham, MD, PhD

• Personalized Medicine for Immune Therapies in Type 1 Diabetes
  Type 1 Diabetes — Is It More than One Disease?
  Todd M. Brusko, PhD
  Antigen-Specific Therapies for Type 1 Diabetes
  Colin Dayan, MD
  Genetically Selected Patients for Targeted Immune Therapy
  Peter Gottlieb, MD
  Response to Immune Therapies — Who Benefits?
  Peter Linsley, PhD

• Health Disparities among People with Obesity
  What Are the Potential Physiological Differences in Adiposity and Energy Expenditure?
  Barbara Gower, PhD
  What Are the Social/Cultural Determinants?
  Leonard E. Egede, MD, MS

What Are the Support and Treatment Paradigms Needed to Address Disparities?
  Fatima Cody Stanford, MD, MD, MPH, MPA, FAAP, FACP, FAHA, FAMWA, FTOS

All Roads Lead to Insulin
  Microtubules and Insulin Granules
  Irina Kaverina, PhD
  A Fluorescent Timer Reporter Enables Sorting of Insulin Secretory Granules by Age
  Melkam A. Kebede, PhD
  The Mitochondria’s Role in Basal Insulin Secretion
  Oriam Shirihai, MD, PhD
  Store-Operated Calcium Channels, Ca Channels, and Basal Insulin Secretion
  Leslie S. Satin, BS, MS, PhD

• Oral Presentations

4:30 p.m.-6:30 p.m.

• Diabetes Retinal Disease — Changing Before Your Eyes
  Treatment of Preproliferative Diabetes Retinopathy and New Grading Scales
  Jennifer Sun, MD, MPH
  Clinical Aspects of Retinal Neurovascular Degeneration in Diabetes
  Stela Vujosevic, MD, PhD, FEBO
  Laboratory Aspects of Retinal Neurovascular Degeneration in Diabetes
  Patrice E. Fort, MS, PhD
  Diabetic Retinopathy in Youth with Diabetes
  Jinan B. Saaddine, MD, MPH

• When COVID-19 Clashes with Diabetes — Data and Experiences Regarding the Impact on People with Diabetes
  Assessing the Intersection of COVID-19, Diabetes, and Mental Health in Adults with Diabetes
  Sarah C. Westen, PhD
  COVID-19’s Impact on the Most Medically and Socially Vulnerable Youth with Diabetes
  Catlin Dennis, MPH
  Diabetes Management in African American Adults During a Pandemic — Lessons from Detroit, MI — A U.S. COVID-19 Epicenter
  Gretchen Piatt, PhD, MPH

Impact of COVID-19 on Psychosocial and Behavioral Factors — Assessing Parents of Young Children with Diabetes
  Christine H. Wang, PhD
  Question and Discussion Period

• Optimizing Health Equity — Solutions-Based Approaches
  Technology and Health Equity in Diabetes Care and Education
  Lori M. Laffel, MD, MPH
  Meaningful Measurements of Population Health — A1C vs. Time-in-Range
  Gloria Wilder, MD, MPH
  The COVID-19 Pivot — Leveraging Innovative Technologies and Diabetes Self-Management Education and Support Services
  Gretchen Youssef, MS, RDN, CDE
  Digital Health and Health Inequity — Target Diabetes Care and Education Services
  Gary Puckrein, PhD

• Disrupting Endocrine Milieu of Pregnancy — Mechanisms of Per-and Polyfluoroalkyl Substances (PFAS) in Maternal–Fetal Health
  PFAS — Metabolic Mechanisms as Endocrine Disruptors Influencing Maternal–Fetal Health
  Tracey Woodruff, PhD, MPH
  PFAS and Risk of Gestational Diabetes and Maternal Adverse Metabolic Outcomes
  Tamarra James-Todd, PhD
  PFAS Placental Transfer in Women with Gestational Diabetes
  Youssef Oulhote, PhD
  PFAS and Placental Function
  Rebecca Fry, PhD
  Neonatal Effects of In Utero Exposure to PFAS
  Justin Conley, PhD
  Question and Discussion Period

• The Year in Review — Highlights of the Past Year in Basic, Translational, and Clinical Sciences
  The Year in Review — Basic Science
  Maureen Gannon, PhD
  The Year in Review — Translational Science
  William T. Cefalu, MD
  The Year in Review — Clinical Science
  Jay S. Skyler, MD, MACP
• Remote Monitoring and Use of Telehealth — Lessons Learned from a Pandemic
Use of Diabetes Technologies for Remote Monitoring in Ambulatory/Rural Settings
Leslie Eiland, MD
Remote Management of Diabetes Emergencies Using Telehealth
Irl B. Hirsch, MD
Advanced Telehealth for a Diabetes Digital Visit
Moshe Phillip, MD
Impact of Telehealth on Quality of Life
Korey K. Hood, PhD
Can Remote Monitoring and Interventions Lessen Health Disparities in Diverse Ethnic/Racial Communities?
Lindsay S. Mayberry, PhD

• Drugs and Genetics — Pharmacogenomic Approaches to Precision Diabetes Treatment
Pharmacogenetics and the Basis of Drug Responses in Diabetes
Ewan Pearson, PhD
Incorporating Genetic Information for Treatment Strategies in Diabetes
Ronald C.W. Ma, MB, BChir, FRCP
Leveraging Genetics for Drug Target Identification
Jose C. Florez, MD, PhD
Future of Drug Discovery Using Stem Cells
Shuibing Chen, PhD

• Joint ADA/EASD Symposium — Novel Insights and Old Controversies around Insulin and Glucagon-Like Signaling
Memorializing the Contributions of Roger H. Unger, MD
Philipp E. Scherer, PhD
The Journey from Glucagon to Incretins in Physiology and Disease
Jens J. Holst, MD, DMSc
Who’s on First? Insulin Resistance or Hyperinsulinemia?
Bettina Mittendorfer, PhD
SGLT2 Inhibitors — Where Do Glucagon, Incretins, and Insulin Fit?
Jonathan Campbell, PhD
Insulin Signaling and Health Span
Michael Ristow, MD
Question and Discussion Period

MONDAY, JUNE 28
8:00 a.m.-10:00 a.m.

• Surgical Considerations in Diabetes Foot Management
Recalcitrant Diabetes Foot Ulcers — When Should You Do Surgery?
Tammer Elmarsafi, DPM, MB, BCh
Pearls of Charcot Reconstruction — When to Pull the Trigger
Michael D. VanPeit, DPM
The Psychological Impact of Diabetes Foot Surgery
Garneisha Torrence, DPM, MHMS
Racial Disparities in Amputation Outcomes — Making the Difference
Foluso Fakorede, MD

• Diabetes and Metabolism across the Lifespan
Age-Related Regulation of Energy Balance and Glucose Homeostasis
Allison Xu, PhD
The Regulation of Healthspan and Longevity by Specific Dietary Macronutrients
Dudley Lamming, PhD
Nutritional Control of Immunometabolism across the Lifespan
John Newman, MD, PhD
Early Programming of Obesity, Type 2 Diabetes, and Aging
Lori M. Zeltser, PhD
Development of Hypothalamic Circuits Controlling Energy Balance
Sebastian G. Bouret, PhD
Question and Discussion Period

• Diabetes Prevention — Addressing Implementation Challenges
Successful Diabetes Prevention Interventions — Lessons Learned
Mike Sampson, MD
Can We Prevent Type 2 Diabetes in Women Who Have Had Gestational Diabetes?
Kerri Lynn Knippen, PhD, MPH, RDN/LD, BC-ADM
Diabetes Prevention in Low- and Middle-Income Countries
Pilvikki Absetz, PhD
Using Digital Technologies to Prevent Diabetes — What Works and Why?
Anne M. Wolf, MS, RDN
Panel Discussion
Mike Sampson, MD
Kerri Lynn Knippen, PhD, MPH, RDN/LD, BC-ADM
Pilvikki Absetz, PhD
Anne M. Wolf, MS, RDN

• Automation and Expanded Use of Technology in the Inpatient Setting — An Update
Automated Inpatient Insulin Orders
Amisha Vallia, MD
How to Optimize Hospital Glucose Management Remotely
Robert J. Rushakoff, MD
Inpatient Use of Continuous Glucose Monitoring to Improve Hyperglycemia
Addie L. Fortmann, PhD
Inpatient Use of Continuous Glucose Monitoring to Prevent Hypoglycemia
David C. Klonoff, MD
Inpatient Use of Hybrid Closed-Loop Systems
Joseph A. Aloi, MD

• Is Continuous Glucose Monitoring (CGM) an Effective Diabetes Management Tool in Primary Care?
CGM Data Automatically Integrated into the Electronic Health Record — What Does It Take?
Amy B. Criego, MD, MS
Successful Use of CGM in Primary Care Depends on Patient Support and Workflow — Lessons from the Mobile Study
Thomas W. Martens, MD
Can CGM Guide Effective and Sustainable Dietary Changes in the Primary Care Setting?
Dana Gershenoff, MS, RD, CD CES
Can CGM Combined with a Smart Pen Improve Insulin Management in Primary Care?
Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP

Could CGM Guided Clinical Decision-Making Be Effective in Primary Care?
Revital Nimri, MD

• Management of Type 1 Diabetes in Adults — 2021 Draft ADA/EASD Consensus Report
Introduction and Methods, Goals, and Targets
Anne L. Peters, MD
Diagnosis of Type 1 Diabetes
J. Hans De Vries, MD, PhD
Schedule of Care
Ruth S. Weinstock, MD, PhD
Monitoring
Irl B. Hirsch, MD
Insulin Therapy
M. Sue Kirkman, MD
Hypoglycemia
Eric Renard, MD, PhD, FRCPEdin
Diabetic Ketoacidosis
Kirsten Nørgaard, MD, DMSc, MHPE
Pancreas and Islet Cell Transplantation
Barbara Ludwig, MD, PhD
Adjunctive Therapy
Jeremy Pettus, MD
Diabetes Self-Management Education and Lifestyle Considerations
Amy Hess Fischl, MS, RDN, LDN, BC-ADM, CDCES
Psychosocial Care
Frank J. Snoek, PhD
Special Populations
Tomasz Klupa, MD, PhD
Emergent and Future Perspectives
Jay S. Sklyer, MD, MACP
Key Knowledge Gaps and Question and Discussion Period
Richard I.G. Holt, PhD, FRCP

• Clinical and Regulatory Hurdles Facing Islet Transplantation
Islet Transplantation — Benefits and Shortcomings
Piotr Witkowski, MD, PhD
Status of Islet Transplantation in the U.S.
Camillo Ricordi, MD
International Experience — Successful Implementation of Clinical Islet Transplantation across the World — What Can the U.S. Learn?
Thierry Berney, MD

• Fibrosis — At the Metabolism–Signalizing Interface
Gut Microbiota at the Interface of Fibrosis and Metabolism
Suzanne Devkota, PhD
Sphingolipid Metabolism and Liver Fibrosis
Jennifer Chen, MD
Liver Inflammation and Fibrosis in Nonalcoholic Steatohepatitis
Ariel Feldstein, MD
Stromal Engagement in Adipose — Adipogenesis vs. Fibrosis
Rana K. Gupta, PhD

• Nuclear Control of Beta-Cell Function
Single-Cell ATAC-Seq in Human Pancreatic Islets and Deep Learning Upscaling of Rare Cells Reveals Cell-Specific Type 2 Diabetes Regulatory Signatures
Stephen Parker, PhD
Tuning Cellular Stress-Response to Protect Postnatal Pancreatic β-Cell Proliferation, Function, and Survival
Guoqiang Gu, PhD
Transcriptional/Epigenetic Regulation of Beta-Cell Function
Chad S. Hunter, PhD
Cooperative Function of Pdx1 and Otc1 in Beta-Cell Proliferation and Compensation
Maureen Gannon, PhD

• Oral Presentations
10:10 a.m.-11:45 a.m.
National Scientific & Health Care Achievement Awards Presentation
Outstanding Scientific Achievement Award Lecture
Kristin J. Nadeau, MD, MS

12:00 p.m.-1:00 p.m.
• Professional Interest Group Discussion on Diabetes Technology — Understanding the Current State of Apps for Supporting Effective Diabetes Care
Introduction
Joseph A. Aloi, MD
Overview of the ADA/EASD Consensus Statement on Diabetes Apps
Anne L. Peters, MD
Reviewing the Diabetes App Landscape — Potential Benefits to Patients and Providers
Jane Jeffrie Seley, DNP, MSN, MPH, GNP, BC-ADM, CDE, CDTC, FAFADE, FAAN
Risks and Challenges of Recommending Mobile Apps for Diabetes — Safety Comes First
Jamie R. Hyatt, RN, BSN, CDCES
Choosing the Right App and Supporting Effective Use — A Case-Based Discussion
Halis K. Akturk, MD
Question and Discussion Period

• Professional Interest Group Discussion on Health Care Delivery and Quality Improvement — Don’t Forget to Ramp Up and Don’t Hesitate to Slow Down — Clinical Inertia in the Treatment of Diabetes
Introduction
Mary K. Rhee, MD
Clinical Inertia — Treatment Intensification
Kamlesh Khunti, PhD, MD, FRCGP, FRCP, FMedSci
Clinical Inertia — Treatment Deintensification
Rajesh Garg, MD
Don’t Forget to Talk to Your Patient — Clinical Inertia Is Not Just about Drugs
Alexander Turchin, MD, MS

• Professional Interest Group Discussion on Pregnancy and Reproductive Health — First Trimester Screening for Diabetes — What Is the Best Approach?
A1C Is Currently the Best Approach for First Trimester Screening
Florence M. Brown, MD
OGTT Is Currently the Best Approach for First Trimester Screening
David Simmons, MA, MBBS, FRACP, FRCP, MD (Cantab)
ADVANCE PROGRAM

There Is No Evidence to Support First Trimester Screening
Erika F. Werner, MD, MS
Debate, Question and Discussion Period

- Professional Interest Group Discussion on Public Health and Epidemiology — Is Diabetes a Risk Factor for Adverse Health Outcomes in Patients with COVID-19?
  
  Introduction
  Elisabetta Patorno, MD, DrPH
  Associations of Type 1 and Type 2 Diabetes with COVID-19-Related Mortality in England — A Whole-Population Study
  Jonathan Valabhji, OBE, MD, FRCP
  Obesity and Mortality among Patients Diagnosed with COVID-19 — Results from an Integrated Health Care Organization
  Sameer B. Murali, MD, MSHS
  Question and Discussion Period

- Professional Interest Group Discussion on Immunology, Immunogenetics, and Transplantation — Clinical Response Endotypes in Type 1 Diabetes
  
  Introduction
  Laura M. Jacobsen, MD
  Teplizumab in Prevention and Response Profiles
  S. Alice Long, PhD
  Regulatory T-Cell Therapy
  TBD
  Multitril Clinical Response Profiles
  Kirsten E. Diggins, PhD

1:00 p.m.-2:00 p.m.

- Session Break (Take this opportunity to visit the Virtual Exhibits and Poster Hall)

2:15 p.m.-4:15 p.m.

- Neonatal Hypoglycemia — Overdiagnosed or Underestimated?
  
  Long-Term Outcomes of Neonatal Hypoglycemia — Clinical Lessons from the Lab
  Raghavendra Rao, MD
  Fetal Hyperinsulinism — Long-Term Outcomes and Lessons for Diabetologists
  Charles A. Stanley, MD
  Epidemiology and Outcomes of Neonatal Hypoglycemia
  Sarbattamma Sen, MD
  Best Practice to Detect and Manage Neonatal Hypoglycemia
  Paul J. Rozance, MD

- Accelerating Care and Education — Digital Health and Diabetes Support — Patient and Provider Perspectives
  
  How Technology Changes the Who, What, and Where of Diabetes Care and Education
  Kelly M. Rawlings, MS
  Telehealth and Diabetes Self-Management Education and Support Services — How We Deliver Services
  Marci Butcher, RD, LN, CDCES, FADCES
  Diabetes Care and Education Specialists-Led Technology Enabled Transitions in Care — Connecting the Diabetes Management Care Team
  Patricia Hathway Montesinos, MSN, APRN, FNP-BC, BC-ADM, CDCES
  Use of Continuous Glucose Monitoring in the Inpatient Setting — Nursing Unit Glucose Telemetry for Hypoglycemia Mitigation
  Ilias (Elias) Spanakis, MD, CDCES

- Joint ADA/ISPAD Symposium — General Population Screening vs. Targeted Screening for Type 1 Diabetes Risk
  
  Updates in General Population Screening for Type 1 Diabetes Risk and Presymptomatic Type 1 Diabetes
  Anette-Gabriele Ziegler, MD
  Updates in Targeted Screening — TrialNet
  Diane K. Wherrett, MD, FRCP
  Genetic Risk Scores to Direct Screening in Type 1 Diabetes
  Richard A. Oram, MD, PhD
  Psychology of Type 1 Diabetes Risk Screening
  Laura B. Smith, PhD
  Cost-Effectiveness of Type 1 Diabetes Risk Screening
  R. Brett McQueen, PhD

- Management of Atypical Diabetes
  
  Diabetes Associated with Pancreatic Disease
  Janet B. McGill, MD
  Posttransplantation Diabetes Mellitus — When to Diagnose, Significance, Use of Technology, and Treatment Challenges
  Marina Basina, MD
  Evaluation and Treatment of Severe Insulin Resistance
  Armen Yerevanian, MD
  Diabetes Secondary to Cancer Therapies
  Mark S. Anderson, PhD, MD

  
  Communicating Risk — The Infectious Disease Epidemiologist’s Perspective
  TBD
  Dissemination, Social Media, and Building Public Trust in Diabetes Risk Communication
  TBD
  Communicating Risk — A Journalist’s Perspective on Scientific Communication
  Gary Schweitzer

- T Cells in Diabetes — Past, Present, and Future
  
  CD4 T Cells in the Pathogenesis of Autoimmune Diabetes
  Kathryn M. Haskins, PhD
  From Mice to Men — Animal Models for the Study of Type 1 Diabetes
  Teresa P. Di Lorenzo, PhD
  The Role of Follicular T Cells in Type 1 Diabetes
  Lucy Walker, PhD
  Chimeric Antigen Receptor T Cells for the Treatment of Type 1 Diabetes
  Megan Levings, PhD

- Interorgan Cross Talk — Metabolites, Proteins, and Extracellular Vesicles
  
  Chemical Control of Energy Metabolism by N-acyl Amino Acids
  Jonathan Z. Long, PhD
  Metabolic Signaling via Brown Fat-Derived Lipokines
  Yu-Hua Tseng, PhD
  Exercise-Induced Hormones in Systemic Metabolism
  Kristin I. Stanford, PhD
  Extracellular Vesicles in Metabolic and Immune Homeostasis
  Anthony W. Ferrante, MD, PhD

81ST VIRTUAL SCIENTIFIC SESSIONS | JUNE 25-29, 2021 | #ADA2021

Speakers and presentation titles are subject to change.
ADVANCE PROGRAM

8:00 a.m.-10:00 a.m.

- Translating Diabetes and Heart Failure Clinical Trial Findings into Clinical Practice
  - Heart Failure with Reduced Ejection Fraction — How to Prioritize among an Array of Available Therapies?
    - Michelle Kittleson, MD, PhD
  - Heart Failure with Preserved Ejection Fraction — Can We Successfully Navigate the “Black Hole” of Heart Failure?
    - Nasrien E. Ibrahim, MD

- Debate — Precision Nutrition — Are We There Yet?
  - Yes, Precision Nutrition Is Ready for Prime Time
    - Paul W. Franks, PhD
  - No, Not Yet Ready for Prime Time
    - Kevin D. Hall, PhD

- Rebuttal
  - Paul W. Franks, PhD
  - Kevin D. Hall, PhD

- Next Chapter in Incretin-Based Therapies — Tirzepatide, a Novel Dual GIP/GLP-1 Receptor Agonist — Results from the First Phase 3 SURPASS Clinical Trials
  - Introduction
    - Daniel J. Drucker, MD
  - SURPASS-1 — A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Three Tirzepatide Doses vs. Placebo in Patients with Type 2 Diabetes Inadequately Controlled with Diet and Exercise Alone
    - Carol H. Wysham, MD

81ST VIRTUAL SCIENTIFIC SESSIONS | JUNE 25-29, 2021 | #ADA2021

Speakers and presentation titles are subject to change.
**ADVANCE PROGRAM**

81ST VIRTUAL SCIENTIFIC SESSIONS | JUNE 25-29, 2021 | #ADA2021

Speakers and presentation titles are subject to change.

**SURPASS-2**—A Phase 3, Randomized, Open-Label Trial Comparing the Efficacy and Safety of Tirzepatide vs. Semaglutide Once Weekly as Add-On Therapy to Metformin in Patients with Type 2 Diabetes
Juan Pablo Frias, MD

**SURPASS-3**—A Randomized, Phase 3, Open-Label Trial Comparing the Efficacy and Safety of Tirzepatide vs. Titrated Insulin Degludec in Patients with Type 2 Diabetes as Add-On to Metformin with or without SGLT2 Inhibitors
Francesco Giorgino, MD, PhD

**SURPASS-5**—A Randomized, Phase 3, Double-Blind Trial Comparing the Effect of the Addition of Tirzepatide vs. Placebo in Patients with Type 2 Diabetes Inadequately Controlled on Insulin Glargine with or without Metformin
Michelle Welch, MD, FACE

**High Dimensional Data in Epidemiologic Research—Gentle Introduction to Methods and Survey of Strengths and Limitations**
Manoj K. Bhasin, PhD

**High Dimensional Data—New Methods for New Discoveries**
Kristi L. Hoffman, PhD, MPH

**High Dimensional Data—High Impact Science or Hype?**
James B. Meigs, MD, MPH

**Single-Cell Perspectives on Metabolic Tissue Function**
Qiong (Annabel) Wang, PhD

**Insulin as a Driver of Cancer**
The Role of Systemic Metabolism in Shaping Tumor Development
M. Celeste Simon, PhD
Insulin Driving Obesity-Related Cancers
Emily J. Gallagher, MD, PhD
Metabolic Pathways as Key Determinants of Cancer Cell Fate Decisions
Lydia Finley, PhD
Diet as Both Cause and Intervention for Cancer
Marcus Goncalves, MD, PhD

**The Islet and Type 1 Diabetes**
Beta Cells in Type 1 Diabetes
Carmella Evans-Molina, MD, PhD
Transcriptional Profiling of Human Islets in Type 1 Diabetes
Golnaz Vahedi, PhD
Omics and Interferon/Cytokine Responses in Type 1 Diabetes
Lorenzo Pasquali, MD, PhD
Pancreatic Beta-Cell Autophagy Is Impaired in Type 1 Diabetes
Amelia K. Linnemann, PhD

**Translating Diabetes and Kidney Disease Clinical Trial Findings into Clinical Practice**
Early Kidney Disease—Interventions to Slow Progression of Chronic Kidney Disease
Maryam Afkarian, MD, PhD
Advanced Kidney Disease—Mitigating Cardiorenal Risk with Renin-Angiotensin-Aldosterone System Blockade (ACEi, ARB, MRA) and SGLT2 Inhibition
Meg J. Jardine, MD, PhD

**Update on SCORED and SOLOIST Cardiovascular and Kidney Outcomes Trials**
Introduction to the Sotagliflozin Journey
Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
Sotagliflozin Background and Study Designs of SOLOIST and SCORED
Lawrence A. Leiter, MD, FRCPC, FACP, FACE, FAHA, FACC
SOLOIST—Main Results
Subodh Verma, MD, PhD, FRCSC
SCORED—Main Results
Mikhail N. Kosiborod, MD
Meta-analysis of SOLOIST and SCORED
Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
Renal Effects of Sotagliflozin
Julia B. Lewis, MD
Independent Commentary
Javed Butler, MD, MPH, MBA